BioByte 045: partnership strategy user-manual biotechs, IRA's first drug list, epigenetic drivers of glioma, in vivo perturb-seq, synthetic data for clinical AI
BioByte 44: docking with AlphaFold, EvolutionaryScale, traversing chemical space, future prospects of LNPs, engineered antitumor bacteria, glial replacement in neurodegenration
BioByte 043: new implications for schizophrenia gene, what characterizes a cell type, multi-kilobase RNA editing, why age of menarche has dropped six years
BioByte 042: 36 billion compounds, genes that keep you alive, spatially-resolved sc-translatomics, predicting the effect of genetic variants on human proteins, myelin dynamics in multiple sclerosis
BioByte 041: NME generation: pharma vs. biotech, validation in AI drug discovery, whole body cellular mapping, deep learning for synergistic drug combos, AI x brain-computer interfaces
BioByte 040: controlling gene expression using bioelectronics, a new benchmark for multimodal biomedical AI, costs and causes of clinical failures in oncology, theories of cancer's origins
BioByte 37: cameras to non-invasively measure neural activity, deep learning for spatial transcriptomics, whole body cellular mapping in mice, 100B-scale transformer for generative protein design